Transparency guideline

Transparency guideline on Lundbeck Japan K. K. and corporate activities in relation to medical institutions. Information about 2016 payments are disclosed below.

  1. Objectives

Lundbeck (Lundbeck Japan K. K. and its headquarters H. Lundbeck A/S) has committed to make utmost efforts to ensure that its corporate activities are to be conducted in an ethically responsible manner. Lundbeck has established the Corporate Code of Conduct and conducted corporate activities based on the Code of Conduct to maintain its reputation as the socially respected and trusted pharmaceutical company. The Code of Conduct includes a provision regarding maintenance of trust and transparency in relation with medical institutions, etc. It is our important responsibility to conduct corporate activities in compliance with the in-house policy for transparency and JPMA’s “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions” as a pharmaceutical company which strongly related to national citizens’ life and health. This considered, the in-house policy for transparency “Transparency Guidelines on Corporate Activities in Relation to Medical Institutions (draft)” was prepared to clearly indicate our policy regarding transparency in cooperate activities in relation to medical institutions, etc.

 

  1. Method of disclosure

Lundbeck Japan K. K. will disclose on its website etc. the information on payment/fund granted to medical institutions, etc., in the previous term after the settlement.

 

  1. Timing of disclosure

Information for the results of each fiscal year from 2012 and onwards will be disclosed in the following year after the closing of the financial accounts. The term of disclosure is one year.

For year 2015 only the annual total will be disclosed for item A Expense for R&D etc below.

From year 2016 and onwards the below items will be disclosed.

 

  1. Scope of disclosure and form of disclosure

A Expense for R&D etc

Expense for R&D etc., includes the costs for clinical studies, new drug development and post-marketing clinical studies conducted in compliance with government regulations such as GCP ordinance, Expense for adverse drug reaction (ADR) and infection report, post-marketing surveillance, etc., conducted based on GPSP ordinance, GVP ordinance and official regulations and payment for CRO in relation to such studies and surveillances are also included.

 

Expenses for disclosure

Form

2016

Total

Expense for collaborative researches

Clinical[1]

Name of funded institution etc. [2]

contract frequency, amount

 

Non-clinical[3]

Annual total and contract frequency,

Name of funded institution etc.

 

Expense for contract researches

Clinical

Name of funded institution etc.

contract frequency, amount

JPY 920,357

Non-clinical

Annual total and contract frequency,

Name of funded institution etc.

 

Expense for clinical studies

 

Name of funded institution etc.

contract frequency, amount

JPY 41,107,441

Expense for post-marketing clinical studies

 

Name of funded institution etc.

contract frequency, amount

 

Expense for adverse drug reaction and infections report

 

Name of funded institution etc.

contract frequency, amount

 

Expense for post-marketing study

 

Name of funded institution etc.

contract frequency, amount

 

Other expenses

 

Annual total

 

 

B. Expense to promote scientific researches

Donations for educational purposes and general donations for promotion of academic researches. Expense for co-hosting medical meetings and donations to support conference such as academic society meeting. Provision of ethical drugs free of charge, in-kind donations, provision of active pharmaceutical ingredients are also included in this category

 

Expenses for disclosure

Form

2016

Total

Donation for educational purpose

xx lab/seminar of xx University:
number of donations and total amount

 

General donation

xx University (xx Foundation):
number of donations and total amount

 

Donations to support academic conferences

xx th xx conference meeting (xx local meeting, xx study meeting):

total amount

 

Expense for co-hosing medical meeting

xx th xx conference meeting/xx workshop:

Total amount

 

 

C Expenses for payment for writing paper, etc.

Expense for lecture, paper, and consultation to disseminate scientific information of in-house medial products, etc.

Expenses for disclosure

Form

2016

Total

Expenses for reward of lectures

Annual total:

xx University xx department/Prof. xx

○○hospital ○○department /head ○○

 

Expense for writing/supervising papers, etc.

Annual total:

xx University xx department/Prof. xx

○○hospital ○○department /head ○○

 

Expense for consigned tasks such as consultation, etc.

Annual total:

xx University xx department/Prof. xx

○○hospital ○○department /head ○○

JPY 1,653,512

Note:After disclosure of the information on payment/fund, those who are interested in viewing detail information can view the information in the place and the time slot indicated by Lundbeck Japan K.K. Procedure detail will be published in the Lu-J web soon after the decision on the procedure.

D Expense for information provision

Expense for lecture, explanatory meetings, etc., necessary for providing scientific information on in-house medical product to health professionals.

Expenses for disclosure

Form

2016

Total

Expense for lecture meeting

Frequency and annual total

 

Expense for explanatory meetings

Frequency and annual total

 

Expense of provision of medical /pharmaceutical literatures, etc.

Annual total

 

 

E Other expense

Expense for entertainment etc., as social conventions

Expenses for disclosure

Form

2016

Total

Entertainment expense, etc.

Annual total

 

 

For request to view the payment detail to HCPs (number of cases, total amount of payments), please contact Lundbeck Japan via email Japan@lundbeck.com with your request.


[1] Expense for clinical researches after phase I

[2] Name of institution, name of organization in the institution and professional affiliation, title and name of relevant person are disclosed based on the contract

[3] Expense for others except clinical researches after phase I

You are about to leave lundbeck.co.jp